CALIDI BIOTH.NEW DL-,0001 Aktie

Calidi Biotherapeutics released results for the quarter ended June 30, 2026, reporting earnings per share (EPS) of -2.94 USD. In the same period last year, EPS was -31.84 USD. No other financial metrics were reported. » More on finanzen.net

Allan J. Camaisa has announced he will let his term as director end at the 2026 annual general meeting; the board of directors will therefore reduce its size from six to five members, effective after the 2026 AGM. Scott Leftwich was appointed to the audit committee with immediate effect. At the same time, Calidi Biotherapeutics successfully completed a bank‑led public offering, raising gross proceeds of about USD 6 million. » More on de.investing.com

Calidi Biotherapeutics completed a public capital increase and generated gross proceeds of approximately $6.0 million through the issuance of 12,094,631 common shares/pre‑funded warrants and three warrant series. The syndicate banks fully exercised the overallotment option (1,575,000 shares plus warrants). Warrants of series J–L have a uniform exercise price of $0.50, with terms of five years (J), one year (K) and six months (L), and include mechanisms to reset the exercise price. The capital measure was carried out at a share price of $0.37 (near a 52‑week low); according to Q3 2025 the company reported a negative free cash flow of $21.8 million and an InvestingPro rating of "weak". » More on de.investing.com